

# Value for money of structural interventions: going beyond HIV-only cost-effectiveness analysis

Michelle Remme<sup>1</sup>, Anna Vassall<sup>1</sup>, Brian Lutz<sup>2</sup>, Jorge Luna<sup>2</sup>, Charlotte Watts<sup>1</sup>

<sup>1</sup> *London School of Hygiene & Tropical Medicine*

<sup>2</sup> *United Nations Development Programme, New York*

**International AIDS Economics Network Pre-Conference**

20-21 July 2012, Washington, D.C.

[www.lshtm.ac.uk](http://www.lshtm.ac.uk)



**STRIVE**  
Tackling the structural drivers of HIV

LONDON  
SCHOOL of  
HYGIENE  
& TROPICAL  
MEDICINE



# Background

- Structural interventions tackle the social drivers of HIV, but also have other health and development primary objectives
- In the context of shrinking HIV funding and pressure for sustainable financing, structural and development interventions with multiple outcomes are an opportunity
- UNAIDS Investment Framework: HIV funding can be “*a catalyst to achieve synergies within the broader health and development programmes and to promote intelligent investment across several sectors*” (Schwartländer et al., 2011)
- Despite their importance, structural interventions could be undervalued and potentially underfinanced
- HIV sector is reluctant to take on such structural interventions as they are expected to have low HIV-specific cost-effectiveness and accrue more benefits to other sectors
  - Result of methodological approach, since typical value for money assessments compare the HIV value *only* to the *full* programme cost, due to the indivisibility/lumpiness of such investments



**STRIVE**  
Tackling the structural drivers of HIV

LONDON  
SCHOOL of  
HYGIENE  
& TROPICAL  
MEDICINE



## Investment

Cash transfer scheme to keep girls in school – Zomba, Malawi

\$10/month provided to in and out-of-school girls (13-22 yrs)

*(Baird et al., 2010 & 2012)*

## Outcomes

35% reduction school drop-out rate



40% reduction early marriages



76% reduction in HSV-2 risk



58% reduction in depression risk



30% reduction in teen pregnancies



64% reduction in HIV risk




→ **Cost per HIV infection averted = \$ 5,000 – 12,500**

> Cost per HIA for other interventions:

\$1,315 for VCT; \$857 for PMTCT;

\$181 for male circumcision

*(Galarraga et al., 2009)*



**STRIVE**  
Tackling the structural drivers of HIV

LONDON  
SCHOOL of  
HYGIENE  
& TROPICAL  
MEDICINE



## Premise:

- HIV resources could be used to co-finance structural interventions with other benefiting (sub-) sectors
- Value for HIV-money of structural interventions could then be assessed, based on the HIV sector's contribution

## Objectives:

- To explore to what extent the HIV sector could consider co-financing structural interventions
- To analyse the consequences of various decision rules from the HIV perspective for the financing of structural interventions



**STRIVE**  
Tackling the structural drivers of HIV

LONDON  
SCHOOL of  
HYGIENE  
& TROPICAL  
MEDICINE



# Economic evaluation methods & decision rules

| Method                            | Outcome unit                               | Implications for structural interventions   | Decision rule/threshold  |
|-----------------------------------|--|---|--|
| Cost Minimisation Analysis (CMA)  | n.a.                                       | Identical outcomes - structural interventions with  | Lowest cost option   |
| Cost-Effectiveness Analysis (CEA) | Natural unit<br>e.g. HIV infection averted | Considers variations in effectiveness between options<br>But single outcome analysis impedes the incorporation of multiple outcomes (within HIV and beyond) | Lowest CER<br>League tables (lowest CERs until budget spent)   |
| Cost-Utility Analysis (CUA)       | DALY<br>QALY                               | Allows for HIV-wide and health sector wide comparisons<br>But single health outcome makes take non-health outcomes into account                             | Lower CERs<br>League tables<br>Below \$25-150/DALY averted<br>Below 1x or 3xGDP/cap per DALY averted |
| Cost-Benefit Analysis (CBA)       | Monetised outcome (\$)                     | Benefits from all sectors can be accounted for and monetised  | Every option where $B > C$ (or $BCR > 1$ )   |
| Cost-Consequence Analysis (CCA)   | Multiple natural units                     | Used to present multiple outcomes, where CBA is not feasible<br>Does not combine measures of benefit into a single measure so cannot be used to rank        | No rule  |

**BUT the HIV sector thinks in terms of CEA outcomes**

**Preferred**

# Proposed HIV Willingness to Pay thresholds for co-financing

## At most...

- Worth funding structural interventions up to the point at which they are considered HIV cost-effective (and affordable)
- Equal to WHO's threshold of GDP per capita per HIV DALY averted

$$\frac{\text{GDP/cap}}{\text{Cost/DALY}} \times \text{Total Costs}$$

## At least...

- Residual programme costs that would not be funded by other sectors, but would correspond CER < GDP/capita threshold

$$\text{Total Costs} - \sum \text{WTP}_{\text{other sectors}}$$

## Its Fair Share...

- Another approach is to apportion the total programme benefits between (sub-) sectors based on CBA and then HIV paying its share
- Provided that BCR > 1 and HIV contribution < WHO threshold

$$\frac{\text{Benefits}_{\text{HIV}}}{\text{Total Benefits}} \times \text{Total Costs}$$



STRIVE  
Tackling the structural drivers of HIV

LONDON  
SCHOOL of  
HYGIENE  
& TROPICAL  
MEDICINE



# Methods (CEA threshold approach)

- CEA calculations:
  - Absolute impact from the trial was calculated based on published figures in the natural units of interest to each sector
  - Based on the DALY formula and/or DCP2 estimates of DALYs per health outcome, we estimated total DALYs averted
  - Maximum WTP for each health outcome = total DALYs averted x GDP per capita
  - Maximum WTP for education outcomes = total impact x highest CER in literature
- Sensitivity analyses:
  - Varied total programme costs based on actual trial costs and estimated costs at scale
  - Varied WTP for health outcomes to WHO CE threshold of 3x GDP per capita
  - Varied WTP for education outcomes to lowest CERs in the literature



**STRIVE**  
Tackling the structural drivers of HIV

LONDON  
SCHOOL of  
HYGIENE  
& TROPICAL  
MEDICINE



# Methods (CBA apportionment)

- Modelling adopted for RethinkHIV analysis:
  - Coverage: 100% of girls currently in secondary school living on less than \$1.25 a day (constrained by existing coverage)
  - Unit costs: estimated from Zomba trial published data and simplified (conservative) assumption of no scale effect
  - HIV impact modelled using estimates of impact on HIV incidence among direct beneficiaries (64% reduction)
  - DALYs estimated using standard formulae
  - Incremental cost per DALY averted includes cost savings and life expectancies adjusted for ART (modelled on current levels of ART coverage)
  - Other benefits modelled = higher earnings, reduced child mortality *(King et al., 2007)*



**STRIVE**  
Tackling the structural drivers of HIV

LONDON  
SCHOOL of  
HYGIENE  
& TROPICAL  
MEDICINE





# Results: CEA thresholds

| (Sub-) Sector                | Outcome                              | Total Zomba impact                  | Total DALYs averted | Threshold per unit of outcome (US\$) | Funding (US\$) | Share of programme costs |                         |
|------------------------------|--------------------------------------|-------------------------------------|---------------------|--------------------------------------|----------------|--------------------------|-------------------------|
|                              |                                      |                                     |                     |                                      |                | At Scale (\$110,250)     | Trial phase (\$275,625) |
| HIV                          | HIV infections averted               | 5.5                                 | 83                  | Min: 303                             | 25,050         | 0%                       | 9%                      |
|                              |                                      |                                     |                     | Max: 327                             | 27,055         | 25%                      | 10%                     |
| Education                    | Drop-outs averted                    | 24                                  | n.a.                | 535                                  | 128,730        | 117%                     | 47%                     |
|                              | Drop-outs re-enrolled                | 193                                 |                     | 79                                   | 15,208         | 14%                      | 6%                      |
|                              | School attendance (additional years) | 144                                 |                     | 303                                  | 58,537         | 53%                      | 21%                     |
|                              | English test scores (0.1 SD gains)   | 708                                 |                     | 5.4                                  | 3,807          | 3%                       | 1%                      |
| Sexual & Reproductive Health | HSV-2 infections averted             | 15.6                                | 78                  | 327                                  | 25,483         | 23%                      | 9%                      |
|                              | Teen pregnancies averted             | 9.8                                 | 38                  | 327                                  | 12,399         | 11%                      | 5%                      |
| Mental Health                | Cases of depression averted          | 45.8                                | 19.6                | 327                                  | 6,410          | 6%                       | 2%                      |
| <b>All sectors</b>           |                                      | Silo budgeting (highest sector WTP) |                     |                                      | 206,283        | Funded                   | Not funded              |
|                              |                                      | Co-financing (total WTP)            |                     |                                      | 277,631        | Funded                   | Funded                  |

# Results: CBA apportionment

|                         | National scale 5-year programme |
|-------------------------|---------------------------------|
| HIV benefits (US\$)     | 75 million                      |
| Share of total benefits | 44%                             |
| HIV costs (US\$)        | 16.8 million                    |
| HIV DALYs averted       | 14,550                          |



|                                    | US\$ |
|------------------------------------|------|
| HIV-only Cost per HIV DALY averted | 996  |
| GDP per capita                     | 327  |
| 3 x GDP per capita                 | 981  |

- In Malawi, national scale programme has benefit-cost ratio of 2.9
- If the HIV sector were to fund only its share of benefits, the cost per HIV DALY averted would go from \$ 2,464 to \$ 996, but would still be above WHO's cost-effectiveness thresholds → not HIV cost-effective



**STRIVE**  
Tackling the structural drivers of HIV

LONDON  
SCHOOL of  
HYGIENE  
& TROPICAL  
MEDICINE



# Affordability in Malawi

| (Sub-) Sector | National scale (million US\$) | National sector budget (million US\$) 2011/12 | Donor disbursements (million US\$) 2010/11 | Average size of donor projects (million US\$) 2010/11 |
|---------------|-------------------------------|---|--|---|
| HIV           | 0.7                           | 78  | 298.2                                      | 2.6   |
| Health        | 1.3                           | 222   |  |   |
| Education     | 6.0                           | 312   | 167.7                                      | 4.1   |
| <b>Total</b>  | 8.0<br>(national programme)   | 1,980<br>(national budget)                    | 1,022<br>(overall)                         | 2.3<br>(overall)                                      |

Based on national sector budget and donor disbursements in 2010/11, the relative contributions for a national-scale scheme appear quite affordable, even assuming trial costs.



**STRIVE**  
Tackling the structural drivers of HIV

LONDON  
SCHOOL of  
HYGIENE  
& TROPICAL  
MEDICINE



# Conclusion

- With silo approach, certain structural interventions with potential could be underfinanced or go unfunded
- Co-financing provides an opportunity to realise development synergies, but will require multi-sectoral coordination/negotiation mechanisms
- Cost-effectiveness is but one criterion in resource allocation, which is a political process – other considerations include equity, acceptability, affordability, foregone programmes, etc.
- Nonetheless, only considering HIV outcomes in the economic evaluation of structural interventions would provide incomplete evidence for policy-makers and could lead to undesirable decisions from an HIV and societal perspective



**STRIVE**  
Tackling the structural drivers of HIV

LONDON  
SCHOOL of  
HYGIENE  
& TROPICAL  
MEDICINE



# Thank you

This work is being pursued as part of the STRIVE (Tackling the structural drivers of HIV) Research Programme Consortium, funded by DfID.

<http://strive.lshtm.ac.uk/>

Presentation also available at <http://same.lshtm.ac.uk/>

Improving health worldwide

[www.lshtm.ac.uk](http://www.lshtm.ac.uk)



**STRIVE**  
Tackling the structural drivers of HIV

LONDON  
SCHOOL of  
HYGIENE  
& TROPICAL  
MEDICINE

